Federated Hermes Inc. Has $45.93 Million Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Federated Hermes Inc. boosted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 162.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,085,986 shares of the company's stock after acquiring an additional 671,881 shares during the period. Federated Hermes Inc. owned 1.72% of Vera Therapeutics worth $45,926,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in VERA. Huntington National Bank acquired a new stake in shares of Vera Therapeutics during the fourth quarter worth $26,000. AlphaQuest LLC bought a new position in Vera Therapeutics during the fourth quarter worth about $34,000. Alliancebernstein L.P. grew its position in shares of Vera Therapeutics by 2.0% during the 4th quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock worth $1,706,000 after buying an additional 800 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after acquiring an additional 1,130 shares during the last quarter. Finally, Corebridge Financial Inc. increased its stake in shares of Vera Therapeutics by 5.8% in the 4th quarter. Corebridge Financial Inc. now owns 22,047 shares of the company's stock valued at $932,000 after acquiring an additional 1,210 shares during the last quarter. Institutional investors own 99.21% of the company's stock.

Wall Street Analysts Forecast Growth

VERA has been the subject of several recent analyst reports. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 target price for the company. Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective on the stock. Guggenheim boosted their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, JPMorgan Chase & Co. lowered their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $64.67.

Vera Therapeutics Stock Up 2.8 %

NASDAQ:VERA traded up $0.62 on Friday, hitting $22.43. 1,535,188 shares of the company's stock were exchanged, compared to its average volume of 758,343. The company has a market cap of $1.43 billion, a P/E ratio of -8.59 and a beta of 1.28. The firm has a 50-day moving average price of $27.58 and a 200-day moving average price of $37.21. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.11. As a group, analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.